Idera Pharma Offers Development Update Related to IMO-9200: Pre-Clinical Data Shows Support of Candidate for Oral Therapeutic Option to Treat IBD
May 18, 2015 at 08:34 AM EDT
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA ...
